Gufic BioSciences Ltd

Mon 17/08/2026,15:59:58 | NSE : GUFICBIO

₹418.20-4.00 (-0.95%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 400.20

Previous Close

₹ 422.20

Volume

297917

Mkt Cap ( ₹ Cr)

₹ 4193.81

High

₹ 432.35

Low

₹ 400.20

52 Week High

₹ 448.00

52 Week Low

₹ 268.00

Book Value Per Share

₹ 66.31

Dividend Yield

0.02

Face Value

₹ 1.00

What's Your Call?

Collective community sentiment on Gufic BioSciences Ltd

Your Vote -

Buy

84.00%

Hold

12.00%

Sell

4.00%

84.00%

25 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

418.20

2421

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

2421

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Gufic BioSciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Gufic BioSciences - Copy of Newspaper Publication

    15 Aug 2026, 2:26PM Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated)

  • Gufic BioSciences - General Updates

    14 Aug 2026, 8:18PM Gufic Biosciences Limited has submitted to the Exchange the Investor Presentation for the quarter ended June 30, 2026

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Investor Presentation

    14 Aug 2026, 8:18PM Investor Presentation for the Quarter ended June 30, 2026 is attached herewith

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Acquisition

    14 Aug 2026, 8:05PM Approval for Incorporation of Subsidiary in the Philippines and Investment by way of Subscription to its Equity Share Capital is attached herewith.

  • Gufic BioSciences - Acquisition

    14 Aug 2026, 7:54PM Gufic Biosciences Limited has informed the Exchange about Acquisition

  • Gufic BioSciences - Results - Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30, 2026

    14 Aug 2026, 7:45PM Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2026 is attached herewith.

  • Gufic BioSciences - Outcome of Board Meeting

    14 Aug 2026, 7:39PM Gufic Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. and information pertaining approval

  • Gufic BioSciences - Board Meeting Outcome for Meeting Held On Friday, August 14, 2026

    14 Aug 2026, 7:34PM Outcome of the Board of Directors Meeting held on Friday, August 14, 2026 is attached herewith.

  • Gufic BioSciences - Copy of Newspaper Publication

    13 Aug 2026, 12:15PM Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 42nd Annual General Meeting of the Company and e-

  • Gufic BioSciences - Business Responsibility and Sustainability Reporting (BRSR)

    12 Aug 2026, 9:54PM Business Responsibility and Sustainability Report for the Financial Year ended March 31, 2026, is attached herewith

  • Gufic BioSciences - Reg. 34 (1) Annual Report.

    12 Aug 2026, 9:43PM Annual Report for the Financial Year 2025-2026 alongwith Notice of 42nd Annual General Meeting is attached herewith.

  • Gufic BioSciences - Record Date

    12 Aug 2026, 9:30PM Gufic Biosciences Limited has informed the Exchange that Record date for the purpose of Dividend & Annual General Meeting is 28-Aug-2026.

  • Gufic BioSciences - Intimation Of Record Date For Final Dividend And 42Nd Annual General Meeting

    12 Aug 2026, 9:27PM Intimation for book closure and record date for the purpose of 42nd Annual General Meeting and payment of final dividend for the financial year ended

  • Gufic BioSciences - Shareholders meeting

    12 Aug 2026, 9:22PM Gufic Biosciences Limited has informed the Exchange regarding Notice of 42nd Annual General Meeting to be held on September 04, 2026

  • Gufic BioSciences - Shareholders Meeting - 42Nd Annual General Meeting Of The Company Scheduled To Be Held On Friday, Septemb

    12 Aug 2026, 9:22PM Intimation of 42nd Annual General Meeting, is attached herewith

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    11 Aug 2026, 2:34PM Intimation of Earnings Conference Call scheduled to be held on August 17, 2026 is attached herewith

  • Gufic BioSciences - Board Meeting Intimation for Consideration And Approval Of, Inter Alia, Unaudited Financial Results (Stan

    10 Aug 2026, 7:10PM Gufic Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider an

  • Gufic BioSciences - Copy of Newspaper Publication

    7 Aug 2026, 7:19PM Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Publication - Notice of the 42nd Annual General Meeting of the Company

  • Gufic BioSciences - Appointment

    31 Jul 2026, 7:46PM Gufic Biosciences Limited has informed the Exchange regarding Re-appointment of Mr. Pankaj J Gandhi as Whole Time Director of the company w.e.f. Sept

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Change in Directorate

    31 Jul 2026, 7:40PM Intimation for Re-appointment of Mr. Pankaj Jayakumar Gandhi (DIN: 00001858) as the Whole Time Director of the Company is attached herewith.

  • Gufic BioSciences - Outcome of Board Meeting

    31 Jul 2026, 7:34PM Gufic Biosciences Limited has informed the Exchange regarding Outcome of Board Meeting held on July 31, 2026.

  • Gufic BioSciences - Board Meeting Outcome for Meeting Held On Friday, July 31, 2026

    31 Jul 2026, 7:33PM Outcome of the Board of Directors Meeting held on Friday, July 31, 2026 is attached herewith\r\n

  • Gufic BioSciences has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    20 Jul 2026, 7:30PM As of June 2026, 72.50% is owned by Indian Promoters and 27.50% by Public. <p align=justify> Top five Promoters holding highest number of shares of Gu

  • Gufic BioSciences - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Jul 2026, 12:15PM Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026 is attached herewith

  • Gufic BioSciences - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    9 Jul 2026, 12:15PM Gufic Biosciences Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018

  • Gufic BioSciences - Copy of Newspaper Publication

    8 Jul 2026, 6:51PM Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement regarding Notice for transfer of equity shares to Investor E

  • Gufic BioSciences - Disclosure under SEBI Takeover Regulations

    29 Jun 2026, 7:46PM Jayesh P. Choksi has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial

  • Gufic BioSciences - Trading Window

    26 Jun 2026, 11:43AM Gufic Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations

  • Gufic BioSciences - Copy of Newspaper Publication

    18 Jun 2026, 4:12PM Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Publication regarding Special Window for Re-lodgement of Transfer and Dema

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    5 Jun 2026, 6:13PM Written Transcript of Earnings Conference Call held on June 01, 2026 at 04:30 PM is attached herewith.

  • Gufic BioSciences - General Updates

    2 Jun 2026, 3:26PM Gufic Biosciences Limited has informed the Exchange about Corrigendum and Clarification to Intimation dated May 29, 2026 regarding Subscription to Sha

  • Gufic BioSciences - General Updates

    2 Jun 2026, 2:20PM Gufic Biosciences Limited has informed the Exchange about Corrigendum and Clarification to Intimation dated May 29, 2026 regarding Subscription to Sha

  • Gufic BioSciences - Corrigendum And Clarification To Intimation Dated May 29, 2026 Regarding Subscription To Shares Of Sarasw

    2 Jun 2026, 3:28PM Corrigendum and Clarification to Intimation dated May 29, 2026 regarding Subscription to Shares of Saraswat Co-operative Bank Limited, is attached her

  • Gufic BioSciences - Corrigendum And Clarification To Intimation Dated May 29, 2026 Regarding Subscription To Shares Of Sarasw

    2 Jun 2026, 2:22PM Corrigendum and Collaboration to Intimation dated May 29, 2026 regarding Subscription to Shares of Saraswat Co-operative Bank Limited is attached here

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    1 Jun 2026, 6:56PM Intimation for Audio Recording of Earnings Conference Call held on June 01, 2026 at 04:30 p.m. has been attached herewith.

  • Gufic BioSciences - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Jun 2026, 6:50PM Gufic Biosciences Limited has informed the Exchange about Link of Recording

  • Gufic BioSciences - Copy of Newspaper Publication

    30 May 2026, 2:59PM Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Publication

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Investor Presentation

    29 May 2026, 11:10PM Investor Presentation is attached herewith

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Change in Management

    29 May 2026, 11:00PM Intimation for Re-appointment of Cost Auditor and Appointment of Internal Auditor is attached herewith

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Acquisition

    29 May 2026, 10:54PM Intimation under Regulation 30 of SEBI Listing Regulations - Further Investment in Saraswat Co-operative Bank Limited is attached herewith.

  • Gufic BioSciences Q4 net profit zooms 158.09% at Rs 20.57 cr

    29 May 2026, 10:50PM The company reported standalone net profit of Rs 20.57 crore for the quarter ended March 31, 2026 as compared to Rs 7.97 crore in the same period last

  • Gufic BioSciences - Corporate Action-Board approves Dividend

    29 May 2026, 10:44PM Intimation for recommendation of final dividend for the financial year 2025-2026 is attached herewith

  • Gufic BioSciences - Results - Audited Financial Results (Standalone And Consolidated) For The Quarter And Financial Year Ende

    29 May 2026, 10:35PM Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026 is attached herewith

  • Gufic BioSciences - Board Meeting Outcome for Meeting Held On Friday, May 29, 2026

    29 May 2026, 10:13PM Outcome of the Board of Directors Meeting held on Friday, May 29, 2026 is attached herewith

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    25 May 2026, 6:27PM Intimation of Earnings Conference Call scheduled to be held on June 01, 2026 is attached herewith.

  • Gufic BioSciences - Analysts/Institutional Investor Meet/Con. Call Updates

    25 May 2026, 6:23PM Gufic Biosciences Limited has informed the Exchange about Schedule of meet

  • Gufic BioSciences - Board Meeting Intimation for Consideration And Approval Of, Inter Alia, Audited Financial Results (Standa

    22 May 2026, 5:29PM Gufic Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider an

  • Gufic receives NMPA China nod for Prilocaine API

    19 Jun 2023 , 11:58AM Gufic Biosciences gets NMPA approval for Prilocaine API

  • Gufic BioSciences

    7 Jun 2022 , 10:08AM Gufic Biosciences: Has launched a new drug delivery system - Dual Chamber Bags at affordable price first time in the India markets. The product launch is basis the collaboration with its European partner. The dual chamber bags come with a peelable aluminium foil allowing the storage of unstable drugs which needs reconstitution just before the administration to the patient. With the launch of this product Gufic aims to capture a major share of Rs 3000 cr lyophilized antibacterial market in India and hence is Positive, though we do not have a coverage on the stock.

  • Gufic Bio gets two patent certificates; stk gains

    6 Jun 2017 , 12:58PM Gufic Biosciences rises over 7% to Rs73.75, after receiving two patent certificates from Intellectual Property India
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Gufic BioSciences Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 1049.3449 911.7374 849.595 659.2153 330.3601
Liabilities 1049.3449 911.7374 849.595 659.2153 330.3601
Equity 10.0283 10.0278 10.0278 9.6945 9.6945
Gross Profit 150.3467 136.3959 145.8714 134.6513 145.7147
Net Profit 63.1487 69.9328 86.1356 79.7048 95.8401
Cash From Operating Activities 44.1931 122.7777 -7.4571 -26.5872 104.4442
NPM(%) 6.71 8.53 10.67 11.54 12.3
Revenue 940.4753 819.806 806.6657 690.6208 779.1556
Expenses 790.1286 683.4101 660.7943 555.9695 633.4409
ROE(%) 9.49 10.51 12.95 11.98 14.41

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
28 Aug 2026 0.1 10 0.02 333.85
22 Sep 2025 0.1 10 0.02 391
18 Sep 2024 0.1 10 0.02 321.05
24 Aug 2022 0.1 10 0.02 243.9
09 Sep 2021 0.1 10 0.02 190.7
03 Nov 2020 0.05 5 0.02 102.1
20 Sep 2019 0.05 5 0.02 59.7
0.05 5 0.02 145.55
28 Aug 2017 0.05 5 0.02 66.25
19 Sep 2016 0.05 5 0.02 41.05
22 Sep 2015 0.05 5 0.02 14.05
18 Sep 2014 0.05 5 0.02 20.9
02 Sep 2013 0.05 5 0.02 5.55
16 Aug 2012 0.05 5 0.02 7.75
16 Sep 2011 0.05 5 0.02 6.05
20 Sep 2010 0.05 5 0.02 6.35
17 Sep 2009 0.05 5 0.02 6.35
11 Dec 2008 0.05 5 0.02 4.45
19 Mar 2008 0.05 5 0.02 9.45
20 Sep 2006 0.16 16 0.02 11.7
22 Sep 2005 0.22 22 0.02 29.75

Peers

Other companies within the same industry or sector that are comparable to Gufic BioSciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 806.10 -0.79 20.39 238.36 -26.19 0.62
Lotus Eye Hospital and Institute Ltd 115.83 0.53 1654.71 868.56 0.39 0.00
Vaishali Pharma Ltd 8.34 -2.00 26.06 5448.75 15.42 0.00
Astec Lifesciences Ltd 580.80 -2.21 0.00 930.61 -363.14 0.00

Company Info

Central Finance Ltd. is a Bombay based company engaged in leasing, bill discounting, loan syndication, merchant banking/advisory services, investments, debt operations, portfolio management scheme, underwriting etc. Central Finance Securities Ltd. is the subsidiary of the company. The company has 100% stake in the subsidiary. 2000 - The Company name of changed to Gufic Biosciences Ltd. 2003 -Forays into vegetables market under the brand 'Gufic seeds'. 2004 -Gufic Biosciences eyes JV in biotech biz 2005 -Gufic Biosciences - Launch of new products 2007 -Gufic Biosciences Ltd has appointed Dr. M C Dhapalapur as Director of the Company on the Board of Directors of the Company with effect from August 01, 2007. 2008 - The Company has set up manufacturing facility for manufacture of Oncology Products. 2012 - The Board of Directors of the Company, inter alia, has recommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2013 -Gufic Biosciences Ltd has irecommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2014 - Ms. Hemal Deasi, Non- Independent Director has been appointed as an Additional Director. -Gufic Biosciences Ltd has recommended a dividend of Re. 0.05 per share on equity share of Rs. 1/- each. 2020-The company received approval for the Scheme of Amalgamation of Gufic Lifesciences Private Limited (the 'Transferor Company') with Gufic Biosciences Limited  (the 'Transferee Company' or 'Company').2021-The Company has approved the proposal for increasing Capital Expenditure to the tune of Rs. 200 Crores out of which around Rs. 180 crores is proposed to be utilized for setting up of the Company's new manufacturing unit and balance Rs. 20 Crores for setting up the Research & Development facility, both in Indore, Madhya Pradesh.2022-The Company approved the signing of Equity Subscription Agreement with M/s. Selvax Pty Limited ('Selvax'), a biotechnology company based in Perth, Western Australia, for subscription of 1,307,000  fully paid ordinary equity shares in Selvax aggregating to 2.67% of its total paid up share capital for a subscription fee of around USD 0.07651 per equity share aggregating to USD 100,000/- and the Company have also entered into a research and collaboration agreement with Selvax to accelerate the commercialization of Selvax's cancer immunotherapy treatment.

Central Finance Ltd. is a Bombay based company engaged in leasing, bill discounting, loan syndication, merchant banking/advisory services, investments, debt operations, portfolio management scheme, underwriting etc. Central Finance Securities Ltd. is the subsidiary of the company. The company has 100% stake in the subsidiary. 2000 - The Company name of changed to Gufic Biosciences Ltd. 2003 -Forays into vegetables market under the brand 'Gufic seeds'. 2004 -Gufic Biosciences eyes JV in biotech biz 2005 -Gufic Biosciences - Launch of new products 2007 -Gufic Biosciences Ltd has appointed Dr. M C Dhapalapur as Director of the Company on the Board of Directors of the Company with effect from August 01, 2007. 2008 - The Company has set up manufacturing facility for manufacture of Oncology Products. 2012 - The Board of Directors of the Company, inter alia, has recommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2013 -Gufic Biosciences Ltd has irecommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2014 - Ms. Hemal Deasi, Non- Independent Director has been appointed as an Additional Director. -Gufic Biosciences Ltd has recommended a dividend of Re. 0.05 per share on equity share of Rs. 1/- each. 2020-The company received approval for the Scheme of Amalgamation of Gufic Lifesciences Private Limited (the 'Transferor Company') with Gufic Biosciences Limited  (the 'Transferee Company' or 'Company').2021-The Company has approved the proposal for increasing Capital Expenditure to the tune of Rs. 200 Crores out of which around Rs. 180 crores is proposed to be utilized for setting up of the Company's new manufacturing unit and balance Rs. 20 Crores for setting up the Research & Development facility, both in Indore, Madhya Pradesh.2022-The Company approved the signing of Equity Subscription Agreement with M/s. Selvax Pty Limited ('Selvax'), a biotechnology company based in Perth, Western Australia, for subscription of 1,307,000  fully paid ordinary equity shares in Selvax aggregating to 2.67% of its total paid up share capital for a subscription fee of around USD 0.07651 per equity share aggregating to USD 100,000/- and the Company have also entered into a research and collaboration agreement with Selvax to accelerate the commercialization of Selvax's cancer immunotherapy treatment.

Parent Organisation

Gufic BioSciences Ltd.

Founded

23/07/1984

Managing Director

Mr.Jayesh P Choksi

NSE Symbol

GUFICBIOEQ

FAQ